Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Lung Cancer (Auckl) · 2017 · PMC5571822 · PMID 28860885

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Subset analysis revealed a nonsignificant trend toward longer median PFS in patients with exon 19 deletions (12.6 months) compared with L858R (9.6 months) and in Asian (12.6 months) versus non-Asian patients (9.7 months).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.